InsidersTradesSigma
Track the BioStem Technologies, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €65.6m. The latest transaction was filed on 20 August 2026 (Levée d'options). Among the most active insiders: POE BRANDON. Every trade is accessible without an account.
Analysts rate BioStem Technologies, Inc. Strong Buy (bullish), based on 1 analysts. Average price target: US$7.00.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
BioStem Technologies, Inc. is a company focused on developing cell therapy and regenerative medicine solutions. It is listed on NASDAQ under the ticker XNAS.